Abstract
The article comments on the drug approval summary for temsirolimus published recently in The Oncologist in regard to the difference observed between the investigators' and independent reviewers' assessments.
MeSH terms
-
Antineoplastic Agents / therapeutic use*
-
Humans
-
Kidney Neoplasms / drug therapy*
-
Kidney Neoplasms / mortality*
-
Sirolimus / analogs & derivatives*
-
Sirolimus / therapeutic use
-
Survival Analysis
Substances
-
Antineoplastic Agents
-
temsirolimus
-
Sirolimus